Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST<sub>2</sub> in Mediating Ligand Effects.

Cancers (Basel) · 2021 · PMC8069349 · PMID 33920241

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

SST 2 and SST 5 IRS showed a slight trend for higher values in tumors from treatment-naïve patients compared to those which underwent SRL therapy before surgery (see Table 1 ), although this difference was not statistically significant (SST 2 p = 0.21, and SST 5 p = 0.65).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.